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Abstract 
BACKGROUND: Hypertension is a global public health crisis. Poorly controlled high blood 
pressure is one of the major factors contributed to this crisis. As lack of treatment adherence is 
often considered the main reason for this failure, the Treatment Adherence Questionnaire for 
Patient with Hypertension (TAQPH) was developed. Since this questionnaire should be reliable 
and strongly valid to be used in clinics and research, this study was performed to test the 
reliability and validity of the TAQPH. 
METHODS: A cross-sectional study was conducted to validate the Persian version of TAQPH 
after using a modified forward/backward translation procedure. A total of 330 hypertensive 
patients were participated in this study. Construct and criterion validity, Cronbachs alpha, and 
test-retest reliability were used to validate the Persian scale. 
RESULTS: Data analysis showed that the scale had excellent stability (intraclass correlation = 0.95) 
and good acceptability of internal consistency (α = 0.80). The exploratory factor analysis (EFA) 
was meaningful but was not confirmed with confirmatory factor analysis (CFA). The scale score 
was correlated with Morisky Medication Adherence Scale (MMAS) score (Ρ = 0.27). 
CONCLUSION: In total, most of the psychometric properties of the 25-item P-TAQHP achieved 
the standard level and were sufficient to recommend for general use. 
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Introduction 
Hypertension is the most prevalent health concern 
among adult patients affecting approximately one 
billion persons worldwide.1 It is one of the major 
risk factors for cardiovascular, cerebrovascular, 
renal diseases, or other end-organ damage leading to 
premature death.2,3 In developing countries, the 
mean awareness, treatment, and control of 
hypertension among men were 40.6, 29.2, and 9.8 
percent, and among women were 52.7, 40.5, and 
16.2 percent, respectively.4 The prevalence of 
hypertension in Iran is estimated by 23% in 30-55 
aged population and by 50% in the population older 
than 55-year-old.5  
According to the World Health Organization, a 
low adherence level of hypertensive patients is one 
of the major reasons for uncontrolled blood 
pressure.6 Javadi showed that only 5% of Iranian 
hypertensive patients comply with their prescribed 
regimen and have control blood pressure.7  
Non-adherence to treatment regimen may lead to 
the worsening of disease, increasing morbidity and 
mortality, frequent hospitalization, and significant 
healthcare costs.8,9 
To understand and facilitate adherence for 
hypertensive patients, the first step is to measure 
patient adherence to recommended treatment 
regimen. Therefore, a valid and reliable tool is 
required. Different adherence scales have been 
designed in various settings to assess patient-
reported compliance levels.10-12 The Morisky 
Medication Adherence Scale (MMAS), the Self-
efficacy for Appropriate Medication Use Scale, the 
Brief Medication Questionnaire, the Medication 
Adherence Rating Scale, and The Hill-Bone 
compliance with High Blood Pressure Therapy 
Scale were developed by Morisky et al.,13,14 Risser et 
al.,15 Svarstad et al.,16 Thompson et al.,17 and Kim et 
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al.,18 respectively. Some of these scales are 
hypertensive specific18 while the others are 
general13,15,16 or specific for other diseases.17 
However, most of these scales are mainly focused 
on medication adherence. The Seventh Report of 
the Joint National Committee (JNC-7) on 
Prevention, Detection, Evaluation, and Treatment 
of High Blood Pressure recommended both use of 
antihypertensive medication and health-promoting 
lifestyle to cure and manage high blood pressure.19 
Beside medication therapy, a healthy diet, weight 
control, and regular exercise all have been shown to 
have potential benefits to improve blood pressure 
control and even reduce medication needs.20 
Regarding these recommendations, Ma et al.1 
developed the Treatment Adherence Questionnaire 
for Patients with Hypertension (TAQPH) in a 
Chinese population. They evaluated psychometric 
properties of the TAQPH and showed that it was a 
reliable and valid scale. According to this scale 
different aspects of hypertensive treatment 
adherence were addressed including medication 
compliance, diet, weight control, exercise, 
stimulation, and stress relive.1 This scale is a more 
comprehensive than other scales which only 
addressed medication compliance, appointment 
keeping, and low salt diet.18 However, literature 
review showed no previous study assessed TAQPH 
validity in other countries. 
In Iran, treatment adherence was mostly 
measured using researcher-designed questionnaires, 
however, the validating process of developing these 
questionnaires was not sufficient.21,22 Dehghan et 
al.23 have evaluated the psychometric properties of 
Hill-Bone Scale and found that this scale was not 
validated in Iranian population. Therefore, a valid, 
reliable, and concise scale are required to measure 
treatment adherence in Iranian hypertensive 
patients. A valid and reliable scale would be helpful 
in both selecting patients that are likely to be poor 
adherents and finding out why patients do not 
comply with their prescribed treatment. The aim of 
this research was to validate the Persian version of 
“TAQPH” (P-TAQPH). 
Materials and Methods 
This was a methodological study conducted in 
educational hospitals in Kerman (the largest city in 
southeastern Iran with a population of 722000) 
where hypertensive patients are being actively 
treated. 
TAQPH 
To evaluate treatment adherence, Ma et al.1 
developed the TAQPH in 2011. TAQPH is a  
4-point Likert-type scale that consisted of 28 items 
grouped into six factors labeled as follows: 
medication (9 items), diet (9 items), exercise  
(2 items), stimulation (3 items), weight control  
(2 items), and relieving stress (3 items). The range of 
potential scores varied between 28 and 112. The 
higher scores indicated a higher level of adherence. 
The authors evaluated the psychometric properties 
of the Chinese version of TAQPH (the original 
version). According to their report, content validity 
index was 0.93. Construct validity had been 
confirmed by the exploratory factor analysis (EFA) 
and confirmatory factor analysis (CFA). Cronbachs 
alpha of the overall questionnaire was 0.86 and the 
test-retest reliability was 0.82.1 
The Persian MMAS-8 (P-MMAS-8) 
P-MMAS-8 is a generic assessment of medication-
taking behavior. This self-reported measure of 
medication taking was developed from a previously 
validated four-item scale14 and supplemented with 
additional items addressing the circumstances 
surrounding adherence behavior. The MMAS 
comprises seven questions with a yes/no response 
format and one question with 5-point Likert 
response. The authors reported acceptable reliability 
and validity of the original version.13 Dehghan et al.24 
and Moharamzad et al.,25 have validated the  
P-MMAS-8. They indicated that the Persian version 
was valid and reliable to use in Iranian context (good 
face validity, significant known-groups validity, and 
significant test-retest reliability). 
Translation 
As the Persian translation did not exist for 
TAQPH, we generated Persian language version of 
this scale using a modified forward/backward 
translation procedure.26,27 In this procedure, the 
original English-language version of the scale was 
first translated into Persian (the Iranian language) 
by two experienced Iranian health experts, 
independently. If there was any difference between 
two translations, the problem was resolved 
through discussion with the translators to yield a 
provisional forward translation. To check the 
adequacy of the first translation, the initial Persian 
version was translated back into English by two 
independent translators who had no previous 
knowledge of the scale. The original and back-
translated versions were discussed in a bilingual 
expert panel to check semantic, idiomatic, 
experiential and conceptual equivalence and to 
resolve the discrepancies.  
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In the next step, 25 hypertensive patients were 
selected to test the face validity of the pre-final 
version of the Persian scale. Each subject should 
completed the scale and was interviewed about the 
meaning of each item. Regarding the results of this 
pilot study, the final version of the Persian scale was 
confirmed after revising the difficult to understand 
and confusing questions. The face validity  
was acceptable. 
The study population consisted of hypertensive 
patients, older than 18 years who were taking at 
least one antihypertensive medication. Patients were 
asked about socio-demographic data such as gender, 
age, marital status, education, and occupational 
status. The patients also were asked for the dates of 
the hypertension diagnosis and the initiation of drug 
treatment. Blood pressure was measured with an 
aneroid sphygmomanometer (ALPK2, Japan) using 
the average of two measurements by  
5-minute interval. To validate the aneroid 
sphygmomanometer, the readings from this 
instrument were compared by those of a mercury 
sphygmomanometer in the same patients. The 
readings were not significantly different. Systolic 
blood pressures (SBP) and diastolic blood pressures 
(DBP) were obtained from the right arm of the 
subjects in a seated position. The subjects were 
required to avoid caffeine (coffee, colas) intake and 
not to smoke 30 minutes before blood pressure 
measurement. If the blood pressure was ≥ 140/90 
mmHg (in patients with diabetes ≥ 130/80 mmHg), 
indicated insufficiently controlled, and if it was < 
140/90 mmHg (in patients with diabetes < 130/80 
mmHg), considered as sufficiently controlled 
hypertension.12,13  
All patients were approached during their 
hospitalization and asked to participate in the study. 
In addition, a convenience sampling technique was 
utilized to select 330 hypertensive patients who had 
been referred to the above-mentioned centers from 
November 2013 to March 2014. Furthermore, we 
used interviews instead of the self-administered 
method for illiterate individuals. 
Tehran University of Medical Sciences (TUMS), 
Iran, approved this project. After approval of 
TUMS and coordination with Kerman University of 
Medical Sciences and the clinical centers, we 
provided information for the subjects. The 
information addressed: (1) The goal and objectives 
of the study, (2) the confidentiality of the data, and 
(3) the participants would be anonymous and were 
free to withdraw from this study at any time. Then, 
the informed consent was obtained verbally. Finally, 
we appreciated participants. 
All analyses were performed using SPSS 
software (version 19.0, SPSS Inc., Chicago, IL, 
USA) and LISREL (version 8.70, Scientific Software 
International, Chicago, IL, USA). Descriptive 
statistics [frequency and percentage, mean, and 
standard deviation (SD)] and analytical statistics 
(Mann-Whitney U, Spearman rho correlation, and 
factor analysis) were used to analyze the data. The 
0.05% significance level was used in this study. 
Psychometric properties of the P-TAQPH were 
evaluated in terms of validity and reliability. 
Construct validity 
To verify construct validity, the factorial design of 
the TAQPH was analyzed using both EFA and 
CFA. EFA was performed to investigate the factor 
structure of the scales by principal component 
analysis (PCA) with varimax rotation.28 At first, we 
tested the factorability of the intercorrelation matrix 
of the 28 items according to the Kaiser–Meyer–
Olkin (KMO) coefficient (should be > 0.50).29 In 
the second step, we conducted a PCA to derive an 
initial solution. Third, we determined the number of 
factors to be extracted according to three different 
criteria: (1) Eigen values > 1, (2) Cattell’s scree plot, 
and (3) items with loadings of 0.4 or greater on each 
factor.30 In the final step, we compared the 
unrotated versus the rotated factor solutions. The 
rotating factors have been applied to obtain a 
simple factor structure that is more easily 
interpreted and compared. We chose the varimax 
rotation as the most popular method of orthogonal 
rotation. Each factor will tend to have either large 
or small loadings of any particular variable. 
Construct validity was further assessed by CFA. 
CFA was used to test the goodness-of-fit of the 
structural equation model in which the observed 
variables (items) correlated with their underlying 
latent constructs (subscales). Model adequacy was 
evaluated by the chi-square test. The main model fit 
indices were the goodness-of-fit index (GFI), 
adjusted GFI (AGFI), comparative fit index (CFI), 
root mean squared error of approximation 
(RMSEA), non-normed fit index (NNFI), and 
standard root mean square residual (SRMR). The 
acceptable model fit is indicated by χ2/degree of 
freedom (df) < 3.0, RMSEA < 0.08, and  
SRMR < 0.8. The values of GFI, AGFI, CFI and 
NNFI indices are 0.9 or greater.28,31,32 
Criterion validity: Concurrent validity 
To assess the concurrent validity, we calculated 
association between scale score and the sufficiently 
controlled versus uncontrolled blood pressure using 
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Mann-Whitney U-test. Furthermore, we calculated 
the correlation of the scale with the SBP, DBP and 
P-MMAS-8 score using Spearman rho coefficient. 
Reliability: Internal consistency and repeatability 
Internal consistency refers to the extent to which 
items of the scale measure the same construct (i.e., 
homogeneity of the scale) and was assessed in our 
study by Cronbachs alpha (should be > 0.70) for 
330 hypertensive patients. We used the test-retest 
method to evaluate the repeatability of the TAQPH. 
To do so, 25 hypertensive patients completed this 
scales twice (at 2-week intervals). To interpret the 
obtained coefficients values above 0.7 were 
considered as excellent reliability.33 
Results 
Socio-demographic characteristics 
In total, 330 hypertensive patients were assessed. 
The mean age of participants was 55.7 ± 8.9 years. 
64.7% (n = 213) of them were men. 75.8%  
(n = 248) were married who their partners were 
alive, 18.3% (n = 60) were widows/ers and the rest 
were single. 42.0% (n = 136) were illiterate. 52.6% 
(n = 172) of patients were employed. 27.9% of 
participants were diabetic. Duration of having 
hypertension was 42.5 ± 28.4 months and initiation 
of hypertension drug therapy was 41.0 ± 28.4 
months. 52.6% (n = 172) of patients have been 
prescribed more than one antihypertensive drug. 
The mean scores of SBP and DBP were  
139.8 ± 13.6 mmHg and 98.0 ± 13.5 mmHg, 
respectively. 85.6% (n = 280) of participants had 
insufficiently controlled blood pressure. The 
hypertensive medication adherence was 69.4 ± 9.6 
according to the P-TAQPH. The distribution of the 
responses to each item in the P-TAQPH is 
presented in table 1. More than half of the 
respondents reported perfect adherence only for 
three of the 28 items (items 9, 19 and 20). 
Construct validity 
For the validity of the construct, the P-TAQPH 
was examined by undertaking PCA with a varimax 
rotation. At first, Bartlett’s test of sphericity was 
used to determine if the sample size were 
appropriate for a factor analysis and to determine 
whether the data came from a sample of the 
normal distributed population. This test showed 
statistical significance (χ2 = 4944.6, df = 378, P < 
0.001). In addition to Bartlett’s test, the KMO 
measure of sampling adequacy was examined. In 
this study, the KMO coefficient was 0.76, 
confirming factorability of the correlation matrix 
of the P-TAQPH. PCA with varimax rotation was 
conducted, and an  
eight-factor solution with an Eigen value > 1 was 
retrieved. The total variance explained by these 
eight factors was 68.8%. Note that the scree plot 
begins to level off after six components, with a 
decrease of the Eigen values from 1.5 to 1.3, 
which was consistent with the number of 
subscales. Therefore, we preferred the six-factor 
solution with an Eigen value (% variance 
explained) of 7.07 (25.2%), 2.54 (9.1%), 2.16 
(7.7%), 1.87 (6.7%), 1.73 (6.2%), and 1.50 (5.4%) 
which together accounted for 60.3% of total 
variance. 26 items (out of 28 items) loaded above 
0.4. Two items did not load in any factors (item 4 
and 20). Four items loaded in two factors (item 5, 
10, 14, and 24). Depending on value of item load, 
positive or negative correlation between item and 
factors, and the underlying meaning, we decided to 
dedicate item 5 to the fifth factor, item 10 and 24 
to the first, item 14 to the third factor. Thus, seven 
items of the “medication subscale” loaded on the 
second and fifth factor. The nine items of diet 
subscale’ loaded in the first and third factor. Two 
items of “stress relieve subscale” loaded in the 
sixth factor and the two items related to “exercise 
subscale” loaded in the fourth factor. One of the 
three items related to “stimulation subscale” 
loaded in the fourth factor and another in the  
sixth factor. 
The two items of “weight control subscale” 
loaded in the first factor. Therefore, the first and 
third factors were related to “diet and weight 
control subscales,” the second and fifth factors to 
“medication subscale,” the fourth factor to 
“stimulation and exercise subscales,” and the sixth 
factor to “stress relieve subscale.” Approximately, 
all factor-related items were meaningful except the 
item 6 which loaded in the first factor and item 28 
which loaded in the second factor. EFA showed 
that the six factors of TAQHP could be merged to 
four factors of “diet and weight control,” 
“medication,” “stimulation and exercise,” and 
“stress relieve” in the observed variables in the 
Iranian context (Table 2). Since items 7 and 19 were 
negatively correlated with the second and sixth 
factors, respectively, these items and the two items  
(4 and 20) not loaded in any factors were candidates 
for omission (Table 2). Note that, to calculate the 
factor analysis, missing responses were replaced 
with means. 
Following the identification of a six-factor solution  
 
  
 
 
www.mui.ac.ir 15 Mar 
 Persian version of the TAQPH 
   80   ARYA Atheroscler 2016; Volume 12; Issue 2 
Table 1. Distribution of the responses to the P-TAQPH 
Question: Would you… 
Missing 
(No) 
Mean 
Response [n (%

)] 
Never Some of the time Most of the time All of the time 
Comply with the total times of prescribed medications? 4 2.90 6 (1.8) 105 (32.2) 130 (39.9) 85 (26.1) 
Comply with the total number of pills consumed daily? 1 3.05 3 (0.9) 81 (24.6) 142 (43.2) 103 (31.1) 
Comply with the required time to take prescribed medications every day? 1 3.15 5 (1.5) 39 (11.9) 186 (56.5) 99 (30.1) 
Never stop taking prescribed medications? 1 3.24 19 (5.8) 28 (8.5) 136 (41.3) 146 (44.4) 
Never increase or decrease tablets by yourself? 2 3.32 3 (0.9) 25 (7.6) 163 (49.7) 137 (41.8) 
Adhere to take prescribed medications, whether in hypertension symptoms or not? 2 2.47 73 (22.3) 101 (30.8) 82 (25.0) 72 (22.0) 
Never forget to take prescribed medications? 2 3.28 1 (0.3) 11 (3.4) 211 (64.3) 105 (32.0) 
Never stop taking prescribed medications when you feel better? 1 3.32 - 15 (4.6) 194 (59.0) 120 (36.5) 
Never stop taking prescribed medications when you feel badly? 2 3.43 12 (3.7) 21 (6.4) 108 (32.9) 187 (57.0) 
Comply with low salt diet? 3 2.53 63 (19.3) 111 (33.9) 71 (21.7) 82 (25.1) 
Comply with low fat diet? 1 2.88 21 (6.4) 103 (31.3) 100 (30.4) 105 (31.9) 
Comply with low cholesterol diet? 1 2.88 46 (14.0) 61 (18.5) 110 (33.4) 112 (34.0) 
Reduce intake of sugar and sweets? 1 2.74 53 (16.1) 78 (23.7) 98 (29.8) 100 (30.4) 
Eat more roughage? 1 2.51 57 (17.3) 104 (31.6) 111 (33.7) 57 (17.3) 
Increase intake of fresh vegetables? 2 2.64 10 (3.0) 159 (48.5) 98 (29.9) 61 (18.6) 
Increase intake of fresh fruits? 3 2.72 10 (3.1) 139 (42.5) 109 (33.3) 69 (21.1) 
Eat more bean products? 3 2.67 11 (3.4) 150 (45.9) 102 (31.2) 64 (19.6) 
Increase intake of low fat dairy products? 2 2.65 24 (7.3) 138 (42.1) 95 (29.0) 71 (21.6) 
Reduce intake of coffee? 2 3.46 27 (8.2) 21 (6.4) 55 (16.8) 225 (68.6) 
Give up drinking? 1 3.90 1 (0.3) 3 (0.9) 23 (7.0) 302 (91.8) 
Give up smoking? 0 2.77 53 (16.1) 105 (31.8) 38 (11.5) 134 (40.6) 
Exercise for 5 times and above per week? 0 1.92 94 (28.5) 183 (55.5) 40 (12.1) 13 (3.9) 
Exercise more than 30 minutes per time? 0 2.04 95 (28.8) 145 (43.9) 70 (21.2) 20 (6.1) 
Limit the total diet? 0 2.41 55 (16.7) 131 (39.7) 97 (29.4) 47 (14.2) 
Control weight? 1 2.14 78 (23.7) 141 (42.9) 95 (28.9) 15 (4.6) 
Leave some time to relax every day? 1 1.84 141 (42.9) 113 (34.3) 61 (18.5) 14 (4.3) 
Adopt methods to relieve stress? 0 1.98 132 (40.0) 105 (31.8) 60 (18.2) 33 (10.0) 
Get a hold of yourself when facing with any incidents? 0 2.78 33 (10.0) 101 (30.6) 102 (30.9) 94 (28.5) 
Valid percent, P-TAQPH: Persian Treatment Adherence Questionnaire for Patients with Hypertension 
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Table 2. Rotated factor matrix: The P-TAQPH 
Question: Would you… 
Rotated matrix 
Decrease unsafe diet 
and weight control 
Medication 
Increase safe 
diet 
Stimulation and 
exercise 
Avoiding self-
medication 
Stress 
retrieve 
Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 Factor 6 
1. Comply with the total times of prescribed medications?  0.74     
2. Comply with the total number of pills consumed daily?  0.88     
3. Comply with the required time to take prescribed medications every day?  0.73     
7. Never forget to take prescribed medications?  -0.64     
28. Get a hold of yourself when facing with any incidents?  0.41     
5. Never increase or decrease tablets by yourself?  -0.52   0.43  
8. Never stop taking prescribed medications when you feel better?     0.68  
9. Never stop taking prescribed medications when you feel badly?     0.79  
6. Adhere to take prescribed medications, whether in hypertension symptoms or not? 0.45      
10. Comply with low salt diet? 0.62  0.42    
11. Comply with low fat diet? 0.79      
12. Comply with low cholesterol diet? 0.88      
13. Reduce intake of sugar and sweets? 0.86      
24. Limit the total diet? 0.52 0.40     
25. Control weight? 0.52      
14. Eat more roughage? 0.63  0.43    
15. Increase intake of fresh vegetables?   0.79    
16. Increase intake of fresh fruits?   0.85    
17. Eat more bean products?   0.76    
18. Increase intake of low fat dairy products?   0.48    
21. Give up smoking?    0.43   
22. Exercise for 5 times and above per week?    0.88   
23. Exercise more than 30 minutes per time?    0.87   
19. Reduce intake of coffee?      -0.61 
26. Leave some time to relax every day?      0.79 
27. Adopt methods to relieve stress?      0.63 
Items not loaded       
20. Give up drinking? - - - - - - 
4. Never stop taking prescribed medications? - - - - - - 
Eigen value 7.07 2.54 2.16 1.87 1.73 1.50 
Percentage of explained variance 25.2 9.10 7.70 6.70 6.20 5.40 
Factor load > 0.40 are mentioned. P-TAQPH: Persian Treatment Adherence Questionnaire for Patients with Hypertension 
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using EFA, CFA was performed to further test the 
factor model that emerged from EFA. The first- 
and second-order CFA models were used. In 
Model 1 (first-order model), we assumed that the  
P-TAQHP was composed of six separate 
correlated dimensions, and in Model 2 (second-
order model), we assumed that a higher-order 
factor accounted for the relationships between the 
individual factors. GFI were examined to 
determine the degree of fit between the data and 
the results of the hypothesized models. In M1, the 
loadings of items were statistically significant at the 
0.05 level (t > 1.96) except for items19 and 20. In 
M2, all of the factors loadings were significant  
(t > 1.96) except for the sixth factor. The χ2-
associated P value was below the 0.050 
significance level in both models (M1: χ2 
=1690.58, df = 335, and P < 0.001) (M2: χ2 = 
1729.07, df = 344, and P < 0.001).  
None of the fit indices reached acceptable levels 
in both models (M1: χ2/df = 5.05, RMSEA = 0.11, 
SRMR = 0.1, GFI = 0.73, AGFI = 0.67,  
CFI = 0.81, IFI = 0.81, and NNFI = 0.79)  
(M2: χ2/df = 5.03, RMSEA = 0.11, SRMR = 0.1,  
GFI = 0.73, AGFI = 0.68, CFI = 0.82, IFI = 0.81, 
and NNFI = 0.79). Consequently, based on these 
models, we could not confirm the structure 
resulting from the EFA. Since items 19 and 20 were 
not significant in the confirmatory model and item 
4 was not loaded on any factors in EFA, these items 
were removed from the model. The modification of 
the structures in M2 showed that the fit indices did 
not improve considerably (modified second-order 
CFA model: χ2 = 1493.64, df = 269 and P < 0.001; 
χ2/df = 5.55, RMSEA = 0.12, SRMR = 0.11,  
GFI = 0.73, AGFI = 0.68, CFI = 0.82, IFI = 0.82, 
and NNFI = 0.80). Based on the fit indices, the 
modified model did not provide a reasonable fit to 
the data. 
Concurrent criterion validity 
To measure the concurrent validity, the correlation 
was assessed between SBP and DBP and the  
P-TAQHP and the P-TAQHP-25 item. None of 
them was correlated with SBP or DBP (P > 0.050).  
Moreover, there were no differences between 
sufficiently control group versus insufficiently in  
P-TAQHP score (Mann-Whitney U = 4.14,  
P = 0.690). The correlation between the P-TAQHP 
and P-MMAS was assessed (Table 3). The 
correlation between these two scales was positively 
significant (P < 0.001). 
Table 3. Association between The P-TAQPH and the 
P-MMAS and systolic and diastolic blood pressure 
Variables 
The P-TAQPH score 
Spearman rho 
coefficient 
P 
Systolic blood pressure ρ = 0.08 0.140 
Diastolic blood pressure ρ = 0.01 0.870 
The P-MMAS score ρ = 0.27 < 0.001 
P-TAQPH: Persian Treatment Adherence Questionnaire for 
Patients with Hypertension; P-MMAS: Persian Morisky 
Medication Adherence Scale 
 
Reliability 
The value of Cronbachs alpha for the P-TAQPH 
was 0.80. The P-TAQPH item-total correlations 
ranged from -0.39 (Item 5) to 0.70 (Item 12). The 
item-total correlations were 0.20 or greater for 19 
items of the P-TAQPH. The Cronbachs alpha 
coefficient of the P-TAQPH increased slightly 
(0.82) when item 5 was not used in the calculation. 
The test-retest reliability of the P-TAQPH indicated 
excellent reliability at a two-week interval with an 
intraclass correlation coefficient (ICC) of 0.95 
[confidence interval (CI): 0.88-0.98] (Table 4). 
Discussion 
According to the results, “the P-TAQPH” had 
sufficient psychometric quality in different aspects of 
reliability, criterion, and construct validity. The 
repeatability of the P-TAQPH was excellent. The 
internal consistency of the P-TAQPH was acceptable. 
The mean score of the P-TAQPH was significantly 
correlated with the mean score of the P-MMAS-8. In 
total, the EFA was meaningful. However, the factors 
structure was not confirmed by CFA. 
Despite an extensive search, we could not access 
relevant articles, and we could not find any article 
that validated this scale in other contexts. The 
different aspects of reliability (repeatability and 
internal consistency) of the P-TAQPH were 
excellent. This was comparable with the original 
version. Ma et al.1 reported that the TAQPH 
reliability was more than 0.80 in both aspects of 
internal consistency and stability. In this study, the 
P-TAQPH was positively correlated with P-MMAS-
8 but it failed to be correlated with SBP and DBP. 
The original scale was correlated with MMAS-4.1 
This was in agreement with our study. However, 
they did not calculate the correlation between 
TAQPH with blood pressure measures. In this 
study, hospitalized patients participated. It is 
assumed that if the patient has low adherence to 
treatment recommendations hospitalization will be  
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Table 4. Corrected item-to-total correlation, Cronbachs alpha and ICC of The P-TAQPH 
Question: Would you… 
Corrected item-to-
total correlation  
(n = 330) 
Cronbachs 
alpha if item 
deleted 
ICC (CI)  
(n = 25) 
1. Comply with the total times of prescribed medications? 0.37 0.79 0.88 (0.74-0.94) 
2. Comply with the total number of pills consumed daily? 0.38 0.79 0.89 (0.78-0.95) 
3. Comply with the required time to take prescribed 
medications every day? 
0.32 0.79 0.91 (0.81-0.96) 
4. Never stop taking prescribed medications? -0.09 0.81 0.97 (0.94-0.99) 
5. Never increase or decrease tablets by yourself? -0.39 0.82 0.86 (0.71-0.93) 
6. Adhere to take prescribed medications, whether in 
hypertension symptoms or not? 
0.25 0.80 0.84 (0.68-0.93) 
7. Never forget to take prescribed medications? -0.30 0.81 1 (1-1) 
8. Never stop taking prescribed medications when you feel 
better? 
-0.18 0.81 1 (1-1) 
9. Never stop taking prescribed medications when you feel badly? -0.04 0.81 0.96 (0.92-0.98) 
10. Comply with low salt diet? 0.63 0.78 0.81 (0.62-0.91) 
11. Comply with low fat diet? 0.68 0.78 0.94 (0.88-0.97) 
12. Comply with low cholesterol diet? 0.70 0.77 0.95 (0.88-0.98) 
13. Reduce intake of sugar and sweets? 0.66 0.78 0.95 (0.90-0.98) 
14. Eat more roughage? 0.66 0.78 0.94 (0.87-0.97) 
15. Increase intake of fresh vegetables? 0.50 0.79 1 (1-1) 
16. Increase intake of fresh fruits? 0.54 0.78 0.98 (0.96-0.99) 
17. Eat more bean products? 0.63 0.78 0.77 (0.54-0.89) 
18. Increase intake of low fat dairy products? 0.47 0.79 0.88 (0.75-0.94) 
19. Reduce intake of coffee? 0.04 0.81 0.88 (0.75-0.94) 
20. Give up drinking? -0.01 0.80 0.80 (0.61-0.91) 
21. Give up smoking? 0.00 0.81 0.73 (0.48-0.87) 
22. Exercise for 5 times and above per week? 0.39 0.79 0.71 (0.45-0.86) 
23. Exercise more than 30 minutes per time? 0.43 0.79 0.73 (0.49-0.87) 
24. Limit the total diet? 0.55 0.78 0.50 (0.15-0.74) 
25. Control weight? 0.36 0.79 0.95 (0.88-0.98) 
26. Leave some time to relax every day? 0.05 0.81 0.88 (0.75-0.95) 
27. Adopt methods to relieve stress? 0.38 0.79 0.84 (0.67-0.92) 
28. Get a hold of yourself when facing with any incidents? 0.34 0.79 0.77 (0.56-0.89) 
The P-TAQPH Cronbachs alpha = 0.80 and ICC = 0.95 (CI: 0.88-0.98); ICC: Intraclass correlation; CI: Confidence interval;  
P-TAQPH: Persian Treatment Adherence Questionnaire for Patients with Hypertension 
 
 
increased. This may affect their blood pressure and 
the correlation coefficient in our study. 
In our EFA, six-factor solution was retrieved 
that was the same as the original version. Item 4; 
“Never stop taking prescribed medications?” and 
item 20; “Give up drinking?” did not load in any 
factors. The majority of Iranians are Muslims. 
According to “Quran” - Muslims holy book - 
drinking alcohols is forbidden (2:219). As it is 
obvious in our findings, more than 90% of subjects 
did not drink alcohols. Therefore, this may affect 
loading of this item. In this study, the six factors 
were related to “decrease unsafe diet and weight 
control” (7 items), “medication” (5 items), “increase 
safe diet” (5 items), “stimulation and exercise” (3 
items), “avoiding self-medication” (3 items), and 
“stress retrieve” (3 items), while in the original 
version, the six factors were related to “medication” 
(9 items), “diet” (9 items), “exercise” (2 items), 
“stimulation” (3 items), “weight control” (2 items), 
and “relieving stress” (3 items).1 The most 
important factor in our study was decreasing unsafe 
diet that was in contrast with the original version of 
TAQPH. In the original version, “medication 
subscale” was the first and important factor. In our 
study, items related to “diet” and “weight control” 
subscales located in the first and third factors. All 
items that related to decreasing harmful food and 
controlling weight such as low salt, fat, cholesterol, 
and sugar, and limiting the total diet located in the 
first factor. 
All items related to increasing useful food such 
as eating roughage, fresh vegetables, fresh fruits, 
bean products, and low-fat dairy products located in 
the third factor. It means that in Iran, patients 
believe that decreasing unsafe food will control 
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weight. They also believe that decreasing unsafe 
food and weight control may have more effect on 
their blood pressure than increasing useful food. In 
Iran, some of patients do not consider to 
hypertension as a disease so they may not pay 
enough attention to prescribed medication. 
Therefore, it is predicted that medication adherence 
is less important in their opinion. In our finding, 
items related to exercises and giving up smoking 
loaded in the fourth factor. It seems that in Iranian 
population these items are related to safe health 
behaviors that are more emphasized by physicians. 
The last factor in our finding was related to stress 
reduction. Item related to “reducing intake of 
coffee” was negatively correlated to that factor 
which was in contrast with the original version. 
Most of the Iranian populations believe that coffee 
has a relaxation effect and it is used to reduce 
tensions. They are not well informed about its 
negative effect on blood pressure.34 Therefore, as it 
is evident in our finding they believed reducing 
intake of coffee is against of stress reduction. This 
may explain some differences between the Persian 
versions and the original Chinese version. In 
addition, the most popular drink in Iran is tea and 
our populations do not use coffee regularly.35 Since 
the effect of tea on hypertension is controversial,34 
we ignored to replace coffee consumption with tea 
consumption. Therefore, we preferred to omit this 
item from the Persian version. The items 6 and 28 
had meaningless loading. The item 6: “Adhere to 
take prescribed medications, whether in 
hypertension symptoms or not?” loaded in diet 
subscale and the item 28: “Get a hold of yourself 
when facing with any incidents?” loaded in 
medication subscales. These were in contrast with 
the original version. Therefore, according to the 
original version, we preferred to keep this item in 
“medication” and “stress retrieve” subscales. In this 
study, the CFA did not confirm the model obtained 
from the EFA. This was in contrast with the 
original version.1 
Information gathered with such a scale, can be 
used to manage patient education and behavioral 
reinforcement, and reveal reasons of non-
adherence. Therefore, it can help the healthcare 
provider to make better treatment decisions.36 This 
scale may be useful to highlight potential reasons 
for medication non-adherence, such as side effects, 
denial of illness because of lack of symptom, 
combine medication, and complexity of drug 
therapy. However, the scale failed to explain the 
other potential risk-factors and reasons of treatment 
non-adherence such as the cost of treatment, 
dependency to medication, lack of patient 
involvement in the care plan, patient’s cultural 
differences, beliefs and previous experience with 
health care system.19 All these factors may have 
direct or indirect influence on treatment adherence. 
Another aspect of antihypertensive treatment 
adherence that was not addressed directly by the 
current scale is that of self-efficacy, which has been 
implicated in a wide range of health behaviors.37 In 
patients with chronic diseases, positive self-efficacy 
appraisals can predict adherence to a variety of 
health-related behaviors including dietary 
recommendations, exercise regimens, and self-
management behaviors.38 
Some study identified that low self-efficacy may 
be a potential barrier to treatment adherence.37 
Beside all pros and cons of the current scale, this 
scale should be used in conjunction with other 
information that may influence on treatment 
adherence such as socio-demographic factors, 
length of illness and treatment, economic status, the 
severity of hypertension, and other associated 
medical concerns.36 
Like other studies, our study had some 
limitations. Hospitalized patients participated in the 
study. We paid attention to the patients’ comfort 
status, and their blood pressures were measured by 
a standard approach, but their responses may have 
been affected by their hospitalization. In addition, it 
is assumed that the hospitalized patient have less 
treatment adherence. Therefore as we only used 
hospitalized patients, this may limit generalization 
of our results. In addition, we used the English 
translation of Chinese version that Ma et al.1 had 
mentioned in their study. They did not explain 
about forward/backward translation procedure. 
Hence, if the English translation of the scale has not 
established in a standard approach, this may affect 
our results. 
Conclusion 
The results of this study showed that “P-TAQPH” 
had excellent stability, good internal consistency, 
meaningful construct validity, and significant 
criterion validity. It seems that the P-TAQPH can 
help healthcare providers assess adherence to the 
hypertension treatment regimen appropriately. The 
results suggested that further study is needed to 
assess the treatment adherence in a different 
population with various degree of adherence. This 
may help the researcher to establish an appropriated 
cut off point according to P-TAQPH. Further 
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studies also are needed to test a more 
comprehensive and multi-dimensional tool to 
measure hypertension-adherence behaviors in the 
Iranian context. 
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